Information about NationDrugs.to
List of countries where we can ship Namenda:
Latest news releases on Namenda:
Namenda (memantine HCl) - Learn more about Namenda and find information for patients and caregivers including Namenda side effects, treatments, indications, FAQs and resources. Namenda (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer’s disease. Namenda is available by prescription only. Namenda should not be ...
Namenda (memantine) reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease. Namenda is used to treat moderate to severe dementia of the Alzheimer's type.
NAMENDA (memantine HCl) Oral Solution. DESCRIPTION. NAMENDA (memantine hydrochloride) is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula:
Compare prices and print coupons for Namenda (Memantine) and other Dementia and Alzheimer's Disease drugs at CVS, Walgreens, and other pharmacies. Prices start at $15.00
Medical use. Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.
Namenda Dosage and Administration. The recommended starting dose of Namenda is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily).
Indications for NAMENDA: Moderate-to-severe dementia of the Alzheimer's type. Adult: Initially 5mg once daily; titrate at intervals of at least 1 week to 5mg twice daily, then to 5mg and 10mg as separate doses, then to 10mg twice daily (prescribe Titration Pak for 1 st 4 weeks).
10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. 1-888-INFO-FDA (1-888-463-6332) Contact FDA
SIDE EFFECTS Clinical Trials Experience. NAMENDA was evaluated in eight double-blind placebo-controlled trials involving a total of 1862 dementia (Alzheimer's disease, vascular dementia) patients (940 patients treated with NAMENDA and 922 patients treated with placebo) for a treatment period up to 28 weeks.
Page 1 of 26 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NAMENDA safely and effectively.